跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

沙罗格列扎

首页药物沙罗格列扎

Investigational

Small Molecule

沙罗格列扎

Saroglitazar

未知生产厂商

Saroglitazar has been investigated for the treatment of Fatty Liver.

生成 AI 研报

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Saroglitazar has been investigated for the treatment of Fatty Liver.

技术标识符

化学式: C₂₅H₂₉NO₄S
CAS 编号: 495399-09-2
UNII ID: E0YMX3S4JD

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES
EP 3004053 B1申请人: CADILA HEALTHCARE LTD优先权: 2013
EP
US
WO
6 件公开
Process for the preparation of saroglitazar pharmaceutical salts
US 10112898 B2申请人: CADILA HEALTHCARE LTD优先权: 2013
US
Pyrrole compound, compositions and process for preparation thereof
US 10385017 B2申请人: CADILA HEALTHCARE LTD优先权: 2015
US
Saroglitazar for the treatment of hepatocellular carcinoma
US 12201609 B2申请人: CADILA HEALTHCARE LTD优先权: 2018
US
Composition comprising high purity pyrrole derivative and method for preparation thereof
US 12201611 B2申请人: ZYDUS LIFESCIENCES LTD优先权: 2020
US
NOVEL CO-CRYSTALS OF SAROGLITAZAR AND SAROGLITAZAR MG SALT
WO 2025115040 A1申请人: ZYDUS LIFESCIENCES LTD优先权: 2023
WO
SAROGLITAZAR FOR THE TREATMENT OF ALCOHOLIC LIVER DISEASES
WO 2025238663 A1申请人: ZYDUS LIFESCIENCES LTD优先权: 2024
WO
NOVEL CO-CRYSTAL OF SAROGLITAZAR WITH POLY(D-GLUCOSAMINE)
WO 2026115579 A1申请人: ZYDUS LIFESCIENCES LTD优先权: 2024
WO
Demethyleneberberine salt as well as preparation method, pharmaceutical composition and application thereof
CN 122187805 A申请人: NANJING KANG CHUAN JI PHARMATECH CO LTD优先权: 2026
CN